Substance dependence

Police Seizures of Psychedelic Drugs Are Soaring Throughout the United States

Retrieved on: 
Tuesday, February 6, 2024
Psilocybin, NYU Langone Health, University, Congress, Seizure, Research, Population health, Acute stress disorder, Substance dependence, Columbia University, HIDTA, NYU, High, National Institutes of Health, MPH, Depression, Mescaline, Illegal drug trade, Fungus, Sale, Bangladesh Technical Education Board, Cancer, LSD, Drug

Their analysis of national and state-level trafficking data revealed that across the country, seizures of psilocybin rose from 402 confiscations in 2017 to 1,393 confiscations in 2022.

Key Points: 
  • Their analysis of national and state-level trafficking data revealed that across the country, seizures of psilocybin rose from 402 confiscations in 2017 to 1,393 confiscations in 2022.
  • The amount of the seized drugs nearly quadrupled, from 226 kilograms to 844 kilograms in the same time frame.
  • "Our findings, which uncover an increase in confiscations of psilocybin, suggest that popularity and availability of this psychedelic may be increasing," said study lead author Joseph Palamar, PhD, MPH.
  • For example, some of the reports in the data reference large shipments that may have been headed to other states for sale.

‘They weren’t there when I needed them’: we asked former prisoners what happens when support services fail

Retrieved on: 
Monday, July 24, 2023
People, Well, Buprenorphine/naloxone, Department, Prison, Housing, Parole, NUAA, Friends, Pharmacy, Prisoner, Trust, Woman, Substance dependence, Rehabilitation, Public housing, History, Imprisonment, Heroin, Switchmen's Mutual Aid Association, Philosophy, Man, AIDS, Work, Canadian International Council, Time, Risk, Drug policy, Empathy, Substance use disorder, Health, Mental health, Psychedelic literature, John Hodgman, Drug, Online shopping, Residential care, Nursing, Creative industries, Maintenance (technical), Centrelink

Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.

Key Points: 
  • Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
  • Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
  • Getting this kind of pre- and post-release support can drastically reduce the risk of the person re-offending.

System failure


    In 2019‑20, 46% of prisoners released in 2017-18 had returned to prison within two years. People who inject drugs are disproportionately more likely to return to prison. This suggests a systemic failure; something is going wrong in the way we provide services to this group of people. For this analysis, “service providers” include actors such as:
    • For example, when Jidah got out of prison, he needed crucial medication for his opioid dependence.
    • And I was that frustrated that it caused me to relapse and get back on the heroin.
    • And I was that frustrated that it caused me to relapse and get back on the heroin.
    • Khish told us he was given some support in getting set up for post-prison life but the help was limited.

Trust is key

    • Being able to trust a service provider is crucial and can enable a smoother transition to community.
    • Ben, however, didn’t find his parole officer “useful”, saying:
      They’re not really there to help you.
    • They’re there to watch over you, but they say they can help.

Getting the right support can be ‘life-changing’

    • Under this new philosophy, Maine’s prisons focus on rehabilitation and growing respect between correctional officers and people who are incarcerated.
    • It can help reduce the chances the prison system is simply reproducing disadvantage and replicating the problems it is ostensibly supposed to solve.
    • If you or someone you know needs help with exiting prison, you can find a list of resources here.
    • The NSW Users and AIDS Association (NUAA) PeerLine on 1800 644 413 may also be helpful.

Mindpath Health releases its 7 Misconceptions About Mental Health

Retrieved on: 
Tuesday, April 18, 2023
Ankle, Substance dependence, Violence, Religion, Education, Homelessness, Genetics, Face, Suicide, MD, Disability, Anxiety, Workplace, Law enforcement, Neurochemistry, COVID-19, Eye, Cancer, DSM-IV codes, Multimedia, Personality, Mental, Depression, Abuse, Love, Child, Health, Injury, Trauma, Mental health, Nursing

DENVER, April 18, 2023 /PRNewswire/ -- Mental health care has come a long way in being integrated into health and wellness plans.

Key Points: 
  • DENVER, April 18, 2023 /PRNewswire/ -- Mental health care has come a long way in being integrated into health and wellness plans.
  • Depression and anxiety rates increased dramatically across the world during the COVID-19 pandemic, and mental health was considered just as important as physical health.
  • Here are some of the biggest misconceptions people have about mental health:
    Sometimes, admitting we need help with a mental health issue can feel like we're admitting a horrible secret.
  • Raising awareness about good mental health care is essential to accepting ourselves and others and the challenges we face.

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

Retrieved on: 
Friday, April 14, 2023
Chewels, US Foods, Neuropharmacology, Dermatitis, Atopic dermatitis, Doctor of Philosophy, Nicotine gum, Incidence, Acquisition, Patient, DMPK, API, Opioid overdose, Disease, Maintenance, Substance dependence, Nicotine, Research, USD, CBG, CDC, CGMP, Addiction, Smoking, Cannabidiol, Skin, Safety, British Columbia Centre for Disease Control, Opioid use disorder, Psoriasis, Translational medicine, European, Immune system, Vitiligo, LC-MS/MS, Opioid, Fatal, ASX, QPS, Food, Pharmaceutical industry, MD, Toxicology, CBD, Cannabigerol, Eurofins Scientific

Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.

Key Points: 
  • Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.
  • QPS is currently drafting pre-investigational new drug (pre-IND) submissions for both the European Union’s European Medicines Agency (‘EMA’) and the US Food and Drug Administration (‘FDA’) for the CannQuit™ and ReneCann™ Products.
  • CEO and Managing Director, Mr Joel Latham said; “QPS is a perfect fit for us to develop these products across the globe.
  • Data collected by Eurofins on the quality and stability of the products will be key components of future regulatory packages.

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Retrieved on: 
Monday, November 28, 2022
Tobacco smoking, Opioid overdose, Cannabinoid, US Foods, United, CDC, Laboratory, Australian Securities Exchange, Chewing, CGMP, National Centre for Disease Control, CBD, Substance dependence, Inflammatory bowel disease, Anxiety, Fatal, Environment, Addiction, Pain, CB1, ASX, OSA, Rheumatoid arthritis, NDA, FDA, Cannabidiol, Concussion, Nicotine, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Death, Patent, American depositary receipt, Opioid use disorder, CDMO, Safety, Acquisition, Contract research organization, Pharmacology, IND, COPD, Opioid, Nicotine gum, Asthma, U.S. FDA, Smoking, Bronchitis, Pharmaceutical industry, Tobacco, Eurofins Scientific

Eurofins will undertake formulation development and manufacture of CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).

Key Points: 
  • Eurofins will undertake formulation development and manufacture of CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).
  • Rapid onset and sustained effect are both qualities desirable for the treatment of addiction disorders.
  • Dr Mark Bleackley, chief scientific officer of Incannex, said: Opioid and nicotine addiction are significant health problems and a major burden on health systems throughout the world.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.

Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression

Retrieved on: 
Tuesday, July 19, 2022
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Ruff, Initiative, OUD, Research, National, Acquisition, CEO, Temple University School of Medicine, Morphine, Neurodegeneration, Motivation, Safety, National Institute, Department, Therapy, Inflammation, Chemokine, NIH, Temple University, Center, Creative, Nucleus accumbens, Opioid use disorder, Maintenance, CCR2, Brain, Substance abuse, Heroin, Substance dependence, Hormone, Dementia, IND, The Center, CBP, OPRM1, National Institute on Drug Abuse, Principles of Neural Science, Pain, Substance Abuse, CXCR4, Hypoventilation, Doctor of Philosophy, Regeneration, Ventral tegmental area, Dopamine, CCR5, MAT, Neuron, Opioid, Pharmaceutical industry, Cereal, Medicine

RAP-103 also reduced the severity of naloxone-precipitated withdrawal responses in morphine dependence, as well as morphine-induced respiratory depression.

Key Points: 
  • RAP-103 also reduced the severity of naloxone-precipitated withdrawal responses in morphine dependence, as well as morphine-induced respiratory depression.
  • In addition, RAP-103 normalized the components of addiction chemistry in the brain that are altered by opioid abuse.
  • These data were published online ahead of print in the September 2022 issue of the peer-reviewed scientific journal Drug and Alcohol Dependence.
  • The results identify chemokine receptor antagonist RAP-103 as a potential treatment to enhance opioid analgesia and inhibit opioid-derived dependence, withdrawal and respiratory depression.

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

Retrieved on: 
Thursday, June 23, 2022
Multiple sclerosis, Nasdaq, Fibrosis, CCR2, Code, Intellectual property, Department, Security (finance), FDA, Substance dependence, Inflammation, Non-alcoholic fatty liver disease, Lipid metabolism, Amyotrophic lateral sclerosis, Gene, Juntendo University, School, Medical laboratory, NAFLD, Arachidonic acid, Medical school, U.S. Securities and Exchange Commission, Tokyo Stock Exchange, Dyslipidemia, Private Securities Litigation Reform Act, Form 8-K, Metabolic syndrome, Neurodegeneration, Annual report, LDL, MD, Hypertriglyceridemia, Failure, PDE, LOXL2, MS, Hepatocyte, IPF, Patient, DCM, Idiopathic pulmonary fibrosis, MPH, MCP-1, Form 10-K, ALS, GLOBE, Glioblastoma, Risk, Pharmaceutical industry

It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.

Key Points: 
  • It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.
  • Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference

Retrieved on: 
Friday, April 22, 2022
Code, ALS, Annual report, Acute respiratory distress syndrome, Substance dependence, Idiopathic pulmonary fibrosis, Nasdaq, Ophthalmology, B. Riley Financial, Non-alcoholic fatty liver disease, DCM, Multiple sclerosis, U.S. Securities and Exchange Commission, Tokyo Stock Exchange, Security (finance), NASDAQ, JD/MBA, MD, MIF, Private Securities Litigation Reform Act, GLOBE, Doctor of Philosophy, Glioblastoma, Chemotherapy-induced peripheral neuropathy, Patient, Form 10-K, Intellectual property, Conference, CIPN, Amyotrophic lateral sclerosis, Failure, Form 8-K, PDE4, Neurodegeneration, NAFLD, IPF, FDA, MS, Risk, Pharmaceutical industry

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).

Key Points: 
  • MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
  • In addition, MN-166 (ibudilast) is being evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
  • MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, April 13, 2022
Code, Soft tissue injury, ALS, Annual report, Acute respiratory distress syndrome, Substance dependence, Idiopathic pulmonary fibrosis, Carbon, Nasdaq, Non-alcoholic fatty liver disease, DCM, Multiple sclerosis, U.S. Securities and Exchange Commission, COVID-19, Tokyo Stock Exchange, Security (finance), NASDAQ, Oxygen saturation (medicine), MD, MIF, Infection, Private Securities Litigation Reform Act, GLOBE, Glioblastoma, Death, Chemotherapy-induced peripheral neuropathy, Patient, Form 10-K, Inflammation, Atmosphere, Intellectual property, CIPN, NIAID, Amyotrophic lateral sclerosis, Failure, Form 8-K, PDE4, Neurodegeneration, NAFLD, Oxygen, Coronavirus, IPF, FDA, Pneumonia, MS, Risk, Virus, MPH, Pharmaceutical industry, Doctor of Philosophy

Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "The last enrolled patients last visit has been completed.

Key Points: 
  • Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "The last enrolled patients last visit has been completed.
  • Acute respiratory distress syndrome (ARDS) is a frequently lethal lung condition caused by excessive inflammation for which there are no effective therapies beyond supportive care.
  • In addition, MN-166 (ibudilast) is being evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
  • MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, patients at risk of developing acute respiratory distress syndrome (ARDS), and substance dependence.

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

Retrieved on: 
Friday, April 8, 2022
Brain, Private Securities Litigation Reform Act, Risk, Amyotrophic lateral sclerosis, Experiment, Multiple sclerosis, University of California, San Diego Performance-Based Skills Assessment, MIF, DCM, Form 10-K, Lists of diseases, Glioblastoma, NASDAQ, Substance dependence, Idiopathic pulmonary fibrosis, Code, Form 8-K, Alcoholism, NIAAA, Neurodegeneration, Patient, Tokyo Stock Exchange, Annual report, ALS, Crave, Camp, MPH, Alcoholism: Clinical and Experimental Research, Failure, PDE10, U.S. Securities and Exchange Commission, Psychiatry, PDE4, MD, Disorder, IPF, NASH, Security (finance), AUD, MS, CIPN, DDA, Intellectual property, Nucleus accumbens, GLOBE, Drinking, Fatty liver disease, FDA, Acute respiratory distress syndrome, Nasdaq, University, Disease, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry, Beer, Doctor of Philosophy

Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.

Key Points: 
  • Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.
  • Multilevel models compared the effects of MN-166 (ibudilast) and placebo on subjective alcohol response.
  • We are pleased that the results of this secondary analysis are consistent with the findings from the primary analysis.
  • Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with limited treatment options.